The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis
Non-randomised trial
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
This study investigated how stopping and then restarting the menstrual cycle pharmacologically impacts bone metabolism in premenopausal women diagnosed with endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
INTRODUCTION: GnRH-analogs induce bone loss. We aimed to investigate the effects of goserelin-induced menstrual cessation (MC) and subsequent menstrual restoration (MR) on bone metabolism (BM).
METHODS: In this prospective cohort study, premenopausal women (PMW) with histologically verified endometriosis (n = 21) received goserelin monthly for 6 months (6 m) resulting in MC and were followed up for another 6 m after MR (12 m). Age- and BMI-matched healthy PMW (n = 20) served as controls for bone mineral density (BMD) measurements. The primary endpoint was changes in lumbar spine (LS)-BMD at 6 m and 12 m; Secondary endpoints were changes in femoral neck (FN)-BMD, bone turnover markers (P1NP and CΤx), sclerostin, and expression of bone-related circulating microRNAs (miRNAs) at 6 m and 12 m.
RESULTS: Goserelin-induced MC reduced LS- and FN-BMD at 6 m (both p < 0.001). From 6 m to 12 m, LS-BMD increased (p < 0.001) but remained below baseline values (p = 0.012), whereas FN-BMD remained stable (p = 1.000). CTx and P1NP levels increased at 6 m (both p < 0.001) and decreased at 12 m (p < 0.001 and p = 0.013, respectively), while CTx (p = 1.000) alone and not P1NP (p = 0.020) returned to baseline. Sclerostin levels did not change. Relative expression of miRNAs targeting RUNX 2 and beta-catenin was significantly downregulated at 6 m compared to baseline (p < 0.001), while the expression of miRNAs targeting osteoblast and osteoclast function at both directions demonstrated a robust increase (up to 400fold) at 12 m (p < 0.001).
CONCLUSIONS: Six months of goserelin-induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone-related miRNAs, changes that are only partially reversed at 6 m after MR.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (69)
- A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis via openalex
- Bone mass in endometriosis patients treated with GnRH agonist implant or danazol via openalex
- Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol via openalex
- Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis via openalex
- Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss via openalex
- Gonadotrophin - releasing hormone analogues for endometriosis: bone mineral density via openalex
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density via openalex
- Gonadotropin releasing hormone agonist therapy and its effect on bone mass via openalex
- Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density? via openalex
- Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate via openalex
- Nafarelin therapy in endometriosis: long-term effects on bone mineral density via openalex
- One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial via openalex
- Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma via openalex
- Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment via openalex
- Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) via openalex
- Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group via openalex
- W2043018121 via openalex
- W2048064562 via openalex
- W2051748491 via openalex
- W2055260481 via openalex
- W2056852027 via openalex
- W2056971814 via openalex
- W2068643120 via openalex
- W2071763079 via openalex
- W2072231974 via openalex
- W2029736267 via openalex
- W2099002965 via openalex
- W2103916420 via openalex
- W2115941653 via openalex
- W2129449855 via openalex
- W2018495408 via openalex
- W2016180299 via openalex
- W2014486464 via openalex
- W2148676055 via openalex
- W2156123548 via openalex
- W2011029117 via openalex
- W1995251672 via openalex
- W2337521034 via openalex
- W2394707818 via openalex
- W1975210295 via openalex
- W1975072114 via openalex
- W1966503218 via openalex
- W1578296754 via openalex
- W2415444424 via openalex
- W2416265216 via openalex
- W2549559842 via openalex
- W2652512382 via openalex
- W2769226496 via openalex
- W2777471722 via openalex
- W2954106967 via openalex
- W2999977872 via openalex
- W3033388364 via openalex
- W3112275605 via openalex
- W4234160457 via openalex
- W4240792267 via openalex
- W1522712517 via openalex
- W6600951853 via openalex
- W2031495520 via openalex
- W6666538158 via openalex
- W6712478114 via openalex
- W6714902491 via openalex
- W6764982404 via openalex
- W6772682592 via openalex
- W6655287665 via openalex
- W2039191702 via openalex
Cited by (5)
- Role of hormonal therapies in endometriosis: balancing efficacy and safety 2026
- Effect of goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis 2025
- Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis 2025
- Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis 2025
- Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study 2023
SciLite annotations
chemicals 4
goserelin
mineral
goserelin
goserelin
Source provenance
- europepmc
- last seen: 2026-10-15T06:08:49.021275+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:33:56.888256+00:00
- scilite
- last seen: 2026-05-18T04:26:01.642840+00:00
- unpaywall
- last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0
· commercial use OK